Resilience and Eli Lilly add $750 million for Ohio drug manufacturing
A $750 million Lilly-Resilience expansion will add KwikPen production in Ohio by early 2027, but the companies have not said whether it will affect supply of any specific GLP-1 medicine.
Resilience and Eli Lilly have expanded their manufacturing partnership with $750 million in combined investment aimed at increasing the supply of medicines made in the United States [1].
The expansion covers Resilience's operations in the Cincinnati region of Ohio, which will now include production of Lilly's KwikPen, a pre-filled injectable pen device that the companies describe as being for innovative medicines treating diabetes and obesity [1]. At least 400 new jobs will be created, bringing the total number of Resilience jobs in Ohio to more than 1,400 [1]. Site preparation is underway, and full operations are expected to begin in early 2027 [1].
The partnership dates to 2023 [1]. According to the companies, it has already produced more than 150 million doses of medicines for U.S. patients in vial and pre-filled syringe formats [1]. Resilience, a contract development and manufacturing organization, runs two facilities in the Cincinnati area that together cover nearly 1 million square feet and employ nearly 1,000 people in manufacturing, operations, quality and regulatory roles [1].
“We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio,” said William S. Marth, Resilience's president and chief executive officer [1]. Edgardo Hernandez, Lilly's executive vice president and president of manufacturing operations, said demand for the company's medicines continues to increase and that scaling complex manufacturing programs requires proven technical capability, an uncompromising commitment to quality and the ability to deliver consistently over time [1].
Several specifics were not disclosed. Neither company said how much of the capacity is intended for GLP-1 or incretin medicines, which Lilly products will be assembled or packaged at the expanded site, how much volume it will handle, or whether the investment will change the price or availability of any particular medicine [1].
One aggregation of the announcement, dated September 11, 2026, describes a 10-year partnership and refers to a $225 million allocation [2]. The companies' own announcement is dated August 19, 2026, calls the arrangement multi-year and gives no term or figure of that kind [1].
Why it matters for patients
The news is about manufacturing capacity, not about a new medicine, a new approval or a change in how GLP-1 drugs are prescribed. Resilience and Lilly describe the goal as strengthening domestic supply of high-demand treatments [1].
KwikPen is one of Lilly's delivery devices for injectable medicines that treat diabetes and obesity [1]. Which medicines will be filled or finished at the Ohio site has not been reported, so it is not yet known whether the expansion will affect the supply of any specific product.
The companies also have not said whether the added capacity will affect prices, insurance coverage or how quickly patients can fill prescriptions. Nothing in the announcement changes which GLP-1 medicines are approved or available now.
What happens next
Site preparation at the Cincinnati-area campus is already underway, with full operations expected in early 2027 [1]. The companies have not given a date for when KwikPen production will start, or a figure for the volume the expanded site will produce [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.